These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 17706543)

  • 1. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ATP site of protein kinases as target for drug development: from natural compounds to gleevec.
    Granot Y
    Isr Med Assoc J; 2002 Aug; 4(8):633-5. PubMed ID: 12183872
    [No Abstract]   [Full Text] [Related]  

  • 3. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
    Sheinerman FB; Giraud E; Laoui A
    J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
    Mol CD; Fabbro D; Hosfield DJ
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
    Kirkland LO; McInnes C
    Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
    Cox KJ; Shomin CD; Ghosh I
    Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
    Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
    J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
    Prudent R; Cochet C
    Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase inhibitors as a therapeutic modality.
    Levitzki A
    Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in the design of selective ATP-competitive kinase inhibitors].
    Deng XQ; Xiang ML; Jia R; Yang SY
    Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases.
    Chène P
    Drug Discov Today; 2008 Jun; 13(11-12):522-9. PubMed ID: 18549979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
    Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
    Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taming the induced folding of drug-targeted kinases.
    Fernández A; Bazán S; Chen J
    Trends Pharmacol Sci; 2009 Feb; 30(2):66-71. PubMed ID: 19097649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
    Duncan JS; Haystead TA; Litchfield DW
    Methods Mol Biol; 2012; 795():119-34. PubMed ID: 21960219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional approach to questions about life, death, and phosphorylation.
    Bernards R
    Cancer Cell; 2005 Jun; 7(6):503-4. PubMed ID: 15950899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.